Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 12/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | SCD | O00767 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22653180 | 0.92 | BRD4 (0.42) | BRD4KDM4EMEN1USP2MAPT | |
| Bromide SCHEMBL15901561 | 0.91 | BRD4 (0.42) | BRD4KDM4EMEN1USP2MAPT | |
| SCHEMBL19405681 | 0.84 | MEN1 (0.65) | BRD4KDM4EMEN1USP2MAPT | |
| SCHEMBL14377117 | 0.82 | KDM4E (0.44) | KDM4EMEN1USP2MAPTIDO1 | |
| SCHEMBL16476452 | 0.80 | KDM4E (0.42) | KDM4EMEN1USP2MAPTIDO1 | |
| SCHEMBL16476439 | 0.80 | KDM4E (0.42) | KDM4EMEN1USP2MAPTIDO1 | |
| Bromide SCHEMBL17254518 | 0.79 | KDM4E (0.42) | KDM4EMEN1USP2MAPTIDO1 | |
| SCHEMBL15705633 | 0.79 | IDO1 (0.46) | BRD4KDM4EMEN1USP2MAPT | |
| SCHEMBL15705634 | 0.78 | MEN1 (0.43) | BRD4KDM4EMEN1USP2MAPT | |
| SCHEMBL14176773 | 0.77 | GSR (0.40) | BRD4KDM4EMEN1USP2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3225112-B1 | PHOTOSENSITISER DISPERSION AND USE OF THE SAME | TRIOPTOTEC GMBH (DE) | 2021-08-18 | — | — | EP | disclosed |
| EP-3838902-A1 | 10H-BENZO[G]PTERIDINE-2,4-DIONE DERIVATIVES, METHOD FOR PRODUCING SAME AND USE OF SAME | TriOptoTec GmbH (DE) | 2021-06-23 | — | — | EP | disclosed |
| EP-2723742-B1 | 10H-BENZO[G]PTERIDINE-2,4-DIONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF | TRIOPTOTEC GMBH (DE) | 2020-11-18 | — | — | EP | disclosed |
| US-20190111168-A1 | PHOTOSENSITIZER DISPERSION, AND USE THEREOF | UNIVERSITÄT REGENSBURG (DE) | 2019-04-18 | — | — | US | disclosed |
| US-20190111168-A1 | PHOTOSENSITIZER DISPERSION, AND USE THEREOF | UNIVERSITÄT REGENSBURG (DE) | 2019-04-18 | — | — | US | disclosed |
| WO-2017167992-A1 | PHOTOSENSITIVE DISPERSION AND USE THEREOF | UNIVERSITÄT REGENSBURG (DE) | 2017-10-05 | — | — | WO | disclosed |
| EP-3225112-A1 | PHOTOSENSITISER DISPERSION AND USE OF THE SAME | Universitätsklinikum Regensburg (DE) | 2017-10-04 | — | — | EP | disclosed |
| US-9745302-B2 | 10H-benzo[g]pteridine-2,4-dione derivatives, method for the production thereof, and use thereof | TRIOPTOTEC GMBH (DE) | 2017-08-29 | — | — | US | disclosed |
| US-20160176877-A1 | 10H-BENZO[G]PTERIDINE-2,4-DIONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF | TRIOPTOTEC GMBH | 2016-06-23 | — | — | US | disclosed |
| US-9241995-B2 | 10H-benzo[G]pteridine-2,4-dione derivatives, method for the production thereof, and use thereof | TRIOPTOTEC GMBH (DE) | 2016-01-26 | — | — | US | disclosed |
| US-20140212459-A1 | 10H-BENZO[G]PTERIDINE-2,4-DIONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF | TRIOPTOTEC GMBH (DE) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176877-A1 | 10H-BENZO[G]PTERIDINE-2,4-DIONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF | DHPS, DOHH, PAH | BRD4 137/4885KDM4E 376/4885MEN1 1722/4885 |
| US-20140212459-A1 | 10H-BENZO[G]PTERIDINE-2,4-DIONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF | DHPS, DOHH, PAH | BRD4 137/4885KDM4E 376/4885MEN1 1722/4885 |
| US-20190111168-A1 | PHOTOSENSITIZER DISPERSION, AND USE THEREOF | PPOX, ALAD, PPID | BRD4 4452/4885KDM4E 2638/4885MEN1 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.